Aurinia 10-Q Details Q3: $83.7M Revenue, $31.7M Net Income, $486.9M Cash
AUPH sits 39% above its 52-week low of $11.96.
Summary
Aurinia's Q3 10-Q confirms $83.7M revenue (+14%), $31.7M net income and $486.9M in cash, with R&D nearly doubling as development programs scale and the tax rate normalizing after the deferred-tax allowance release.
Key Events · Earnings and Guidance · AUPH
-
Q3 Revenue $83.7M, Up 14%
Total revenue for the three months ended September 30, 2026 was $83.7 million versus $73.5 million a year earlier, driven by LUPKYNIS net product sales of $79.4 million (+12%).
-
Net Income $31.7M, EPS $0.23
Operating income was $35.4 million and diluted EPS $0.23; nine-month net income reached $103.5 million versus $76.4 million in 2025.
-
Cash Grows to $486.9M
Cash, equivalents, restricted cash and investments rose to $486.9 million from $398.0 million at December 31, 2025, after $74.9 million of share repurchases in the nine months.
-
Tax Rate Normalizes to 18.1%
Q3 income tax expense was $7.0 million versus $0.4 million a year ago; the deferred-tax valuation allowance was fully released at year-end 2025, so no unrecognized DTAs remain to offset expense.
Analysis · AUPH · Life Sciences
Behind this morning's earnings release sits the 10-Q, and its audited detail holds up: revenue of $83.7M (+14%), with LUPKYNIS contributing $79.4M, operating income of $35.4M, and nine-month operating cash flow of $131.5M, up 46%. Cash rose to $486.9M from $398.0M at year-end even after $74.9M of buybacks, so no financing need looms. The structural change is tax: with the deferred-tax valuation allowance fully released at the end of 2025, the effective rate jumped to 18.1% in Q3 from 1.3% a year ago, meaning net income growth will now track pre-tax results rather than benefiting from a one-time tax shield. R&D roughly doubled to $16.6M as aritinercept and the PRESERVE Phase 4 study ramp, and that is the spend line to watch against the raised $325M-$330M revenue guide.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AUPH was trading at $16.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $11.96 to $19.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.